Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7532089 | 0.87 | CYP1A2 (0.42) | DRD2DRD3ATMSLC6A2SLC6A4 | |
| SCHEMBL8276483 | 0.84 | DRD2 (0.58) | ALDH1A1GAADRD2DRD3ATM | |
| Hydrochloric Acid SCHEMBL10705356 | 0.83 | ATM (0.59) | ALDH1A1DRD2DRD3ATMHTR2A | |
| SCHEMBL334337 | 0.80 | ALDH1A1 (0.46) | ALDH1A1HSD17B10GAASLC6A2SLC6A4 | |
| SCHEMBL13920515 | 0.78 | SLC6A2 (0.43) | ALDH1A1DRD2DRD3ATMSLC6A2 | |
| Hydrochloric Acid SCHEMBL8156228 | 0.77 | P2RX7 (0.44) | DRD2DRD3ATMSLC6A2SLC6A4 | |
| SCHEMBL5805251 | 0.77 | ALDH1A1 (0.58) | ALDH1A1HSD17B10DRD2DRD4DRD3 | |
| SCHEMBL31176347 | 0.76 | ADRB1 (0.54) | HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL3653056 | 0.76 | ADRB1 (0.54) | HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL255189 | 0.76 | HTR1A (0.68) | ALDH1A1HSD17B10DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118198-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | ZULA DIAGNOSTICS AB (SE) | 2009-05-07 | — | — | US | claimed |
| EP-2019819-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | Neobiotics AB (SE) | 2009-02-04 | — | — | EP | claimed |
| US-20080255055-A1 | Use of Derivatives of Dipeptides for the Manufacture of of a Medicament for the Treamtent of Microbial Infections | NEOBIOTICS AB (SE) | 2008-10-16 | — | — | US | claimed |
| WO-2007129952-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | NEOBIOTICS AB (SE) | 2007-11-15 | — | — | WO | claimed |
| EP-1824873-A1 | USE OF DERIVATIVES OF DIPEPTIDES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF MICROBIAL INFECTIONS | Neobiotics AB (SE) | 2007-08-29 | — | — | EP | claimed |
| US-20060116327-A1 | Dipeptide derivatives with active agents to formulate one composition to reduce, eliminate more than one microorganism; effect against a broad spectrum of microorganisms; mechanism of action on pathogen may be on a basic level; low probability for developing resistance | NEOBIOTICS AB (SE) | 2006-06-01 | — | — | US | claimed |
| WO-2006052201-A1 | USE OF DERIVATIVES OF DIPEPTIDES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF MICROBIAL INFECTIONS | NEOBIOTICS AB (SE) | 2006-05-18 | — | — | WO | claimed |
| US-8097582-B2 | Peptide derivatives useful as antimicrobial agents and for treating wounds | NEOBIOTICS AB (SE) | 2012-01-17 | — | — | US | disclosed |
| US-20100247648-A1 | ANTIMICROBIAL COMPOUNDS | NEOBIOTICS AB (SE) | 2010-09-30 | — | — | US | disclosed |
| US-7691805-B2 | Antimicrobial compounds | NEOBIOTICS AB (SE) | 2010-04-06 | — | — | US | disclosed |
| US-20090118198-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | ZULA DIAGNOSTICS AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-2019819-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | Neobiotics AB (SE) | 2009-02-04 | — | — | EP | disclosed |
| US-20080255055-A1 | Use of Derivatives of Dipeptides for the Manufacture of of a Medicament for the Treamtent of Microbial Infections | NEOBIOTICS AB (SE) | 2008-10-16 | — | — | US | disclosed |
| WO-2007129952-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | NEOBIOTICS AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| EP-1824873-A1 | USE OF DERIVATIVES OF DIPEPTIDES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF MICROBIAL INFECTIONS | Neobiotics AB (SE) | 2007-08-29 | — | — | EP | disclosed |
| US-20060116327-A1 | Dipeptide derivatives with active agents to formulate one composition to reduce, eliminate more than one microorganism; effect against a broad spectrum of microorganisms; mechanism of action on pathogen may be on a basic level; low probability for developing resistance | NEOBIOTICS AB (SE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006052201-A1 | USE OF DERIVATIVES OF DIPEPTIDES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF MICROBIAL INFECTIONS | NEOBIOTICS AB (SE) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116327-A1 | Dipeptide derivatives with active agents to formulate one composition to reduce, eliminate more than one microorganism; effect against a broad spectrum of microorganisms; mechanism of action on pathogen may be on a basic level; low probability for developing resistance | ARG1, ARGLU1, VIP | ALDH1A1 4362/4885HSD17B10 3974/4885HIF1A 1109/4885 |
| US-20080255055-A1 | Use of Derivatives of Dipeptides for the Manufacture of of a Medicament for the Treamtent of Microbial Infections | VIP, ARG1, PEPD | ALDH1A1 3543/4885HSD17B10 4445/4885HIF1A 610/4885 |
| US-20090118198-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | VIP, NGLY1, ARG1 | ALDH1A1 4435/4885HSD17B10 4356/4885HIF1A 433/4885 |
| US-20100247648-A1 | ANTIMICROBIAL COMPOUNDS | ARG1, C1R, ARG2 | ALDH1A1 4240/4885HSD17B10 3310/4885HIF1A 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.